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Between 2009 and 2011, 18 431 laboratory-confirmed 
cases of measles were reported from the nine 
provinces of South Africa (SA) (cumulative incidence 
3/100 000 population).[1] The highest incidence 
was in children <1 year of age (603/100  000). The 
incidence in infants <6 months of age was 302/100 000, in those 
aged 6 - 8 months 1 083/100,000, and in those aged 9 - 11 months 
724/100 000. Forty-eight per cent of the patients were <5 years of age, 
with the result that significant additional demand was placed on 
child health services.[1] A single strain of measles virus (genotype B3) 
circulated throughout this outbreak.
Across SA in 2002, following the ‘catch-up’ campaign in 1996 - 1997, 
there was a 96% decrease in patients admitted with measles, and a 100% 
decline in reported deaths.[2] When the outbreak in 2009 occurred, a 
nationwide mass vaccination campaign was therefore undertaken over 
a 2-week period in mid-April 2010. Concern was raised that, compared 
with the effectiveness of the previous vaccination campaign, the one 
in 2010 lacked the same uptake levels, with anecdotal reports of poor 
uptake on the part of some parents and schools.[3]
As an immediate consequence of the measles outbreak, a cohort 
of eight HIV-infected patients with probable (n=3) or definite (n=5) 
measles inclusion body encephalitis (MIBE) were managed in the 
neurology department at Groote Schuur Hospital, Cape Town, SA, 
between July and October 2010.[4,5] MIBE manifests between 1 and 7 
months after acute measles infection. Patients present with seizures, 
often epilepsy partialis continua, and altered cognitive awareness. [6] 
The mortality rate is 85%, and survivors are left with significant 
neurosequelae. In the case series reported from the Western Cape 
Province, six of the eight patients died and all followed the clinical 
course reported above.[4,5] The youngest confirmed patient was 14 
years of age. Anecdotally, two additional children, aged 10 (male) 
and 11 (female) years and suspected to have MIBE, were managed 
at Red Cross War Memorial Children’s Hospital, Cape Town, with 
a parallel clinical course and findings on neuroimaging; both these 
patients also had HIV infection. However, serum and cerebrospinal 
fluid (CSF) screening in these patients, and even brain biopsy in one 
patient, failed to identify the measles virus. Albertyn et al.[4] suggested 
that additional cases of MIBE were probably occurring across the 
country, but were potentially not detected without screening for the 
virus or completing the required notifications; in addition, some 
patients may have died before reaching medical services.
Five years after the most recent (2010) measles outbreak in SA, 
a new cohort of children have presented with subacute sclerosing 
panencephalitis (SSPE).
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Between 2009 and 2011, there was an outbreak of measles throughout South Africa (SA). The largest age category infected was children <5 
years of age. In 2014, four patients, with a median age of 4 years and 5 months (range 4 years 3 months - 4.5 years), three males and one 
female, presented with subacute sclerosing panencephalitis (SSPE). All were infected with measles during the period of the 2009 - 2011 
outbreak in early infancy, at a time when their immune systems were immature and before they were vaccinated against the measles virus. 
One patient was immunocompromised, with vertically acquired HIV infection. All the children presented with cognitive and behavioural 
decline, abnormal movements and medically intractable myoclonic and atonic seizures. Outcome was poor in all and no reversibility was 
evident with standard therapeutic interventions. Optimal seizure control with carbamazepine is reported in patients with SSPE. Three of 
our patients who received carbamazepine experienced improved seizure control, but their neuroregression continued. Since submission of 
this case series, patient 1 (see Table 1) has died, and a further child has presented with the same clinical phenotype as described. On the 
basis of this clustering of patients in the Western Cape Province, SA, it is important to screen children admitted with acute cognitive decline 
and intractable seizures for SSPE, especially those who were infants during the measles outbreak.
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Case summaries
Between April and June 2014, four children 
were admitted to Red Cross War Memorial 
Children’s Hospital with intractable seizures 
and neuroregression (Table 1). All had 
previously been well, and they were aged 
between 4 years and 3 months and 4.5 
years (median 4 years and 5 months) at 
presentation. Typical seizures consisted of 
recurrent myoclonic and atonic seizures. The 
atonic seizures manifested as ‘head nods’. 
Cognitive function was progressively affected 
in all. Patient 3 had optic disc swelling 
at presentation, which remained static and 
was not associated with evidence of raised 
intracranial pressure. One of the children 
(patient 1) was immunocompromised as 
a result of HIV-1 infection, but had an 
undetectable viral load on antiretroviral 
therapy (ART).
CSF and serum analysis showed raised 
measles antibody titres, confirming the 
diagnosis of SSPE. Prior analysis with the 
polymerase chain reaction (PCR) for measles 
was negative on CSF in all, and initially 
led to the misleading assumption that the 
children did not have SSPE. Additional 
results included normal findings on CSF 
analysis and microscopy in all patients. 
CSF oligoclonal bands were positive in all 
the patients except patient 1. Findings on 
magnetic resonance imaging (MRI) (Figs 1A, 
1B, 2A and 2B) varied from unremarkable at 
presentation to the typical nonspecific white 
matter hyperintensities described in SSPE.[6] 
Electroencephalograms (EEGs) (Figs 3 - 6B) 
typically demonstrated generalised periodic 
spike, or polyspike, wave discharges with 
suppression of background activity, which 
were intermittent and correlated with seizure 
events. Serial studies confirmed progressive 
deterioration with increasingly suppressed 
background activity.
Prior measles infection was rarely 
reported on routine history taking and had 
to be actively sought. Further questioning 
of the accompanying adults revealed that all 
the children had been infected with measles, 
either definitely or based on a history of 
a typical rash, between 3 months and 1 
year of age. All would have received their 
first measles vaccination at 9 months of 
age, but were younger than this when they 
contracted measles.
Treatment in all children involved multi-
ple combinations of antiepileptic drugs 
(AEDs), but with minimal response. How-
ever, improved control of myoclonic and 
atonic seizures was evident following the 
introduction of carbamazepine in three of 
the four children. Patient 3 remained on 
lamotrigine, as his seizures appeared to 
respond to this agent. In the management 
of patient 1, since carbamazepine is usually 
avoided in combination with ART, infectious 
diseases specialists were consulted; given 
the strong data supporting the use of 
carbamazepine in patients with SSPE, 
the drug was initiated and levels of both 
carbamazepine and ART closely monitored. 
To date no further complications have 
occurred and the patient has experienced 
improved seizure control.
All the patients had progressive neuro-
cognitive regression, loss of ambulation and 
speech, feeding dependency and frequent 
Fig. 1A. Patient 2. MRI of the brain (T2-weighted 
fluid attenuation inversion recovery (FLAIR)) 4 
months after presentation. Imaging demonstrates 
nonspecific, bifrontal white matter foci of signal 
abnormality (a).
A
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Fig. 1B. Patient 2. MRI of the brain (T2-
weighted FLAIR) 8 months after presentation, 
demonstrating an interval progression of signal 
abnormality in the frontal lobes (a). The imaging 
shows high signal, and there is corresponding 
restricted diffusion in the deep white matter of 
both frontal lobes (a), the genu of the corpus 
callosum (b) and the right centrum semi ovale 
(c). The entire right temporal lobe is now swollen 
with high-signal white matter and blurring of 
the grey/white junction (d). This area is also 
restricted. The medial thalami and left parietal 
white matter are also involved (e). 
B
a
a
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Fig. 2A. Patient 3. MRI of the brain (T2-weighted 
FLAIR) 1 month after presentation, showing diffuse 
nonspecific small areas of hyperintensity scattered in 
the superficial and deep white matter in the frontal 
temporal lobes bilaterally, with no mass effect (a). 
A
a a
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Fig. 2B. Patient 3. MRI of the brain (T2-weighted 
FLAIR) 6 months after presentation, showing marked 
interval deterioration with high signal in the white 
matter throughout the left cerebral hemisphere, most 
prominent in the parietal lobe (a). This also involves 
the posterior corpus callosum and posterior limb of 
the left internal capsule (b). Similar changes, but to a 
lesser extent were evident in the right parietal white 
matter. There was global volume loss within the left 
cerebral hemisphere, also involving the left cerebral 
peduncle and midbrain. In view of the previous 
measles infection, these findings were considered to 
be in keeping with SSPE with interval worsening.
b
a
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seizure activity. Based on the four stages of 
the disease progression, as summarised in 
Table 2, three patients had reached stage 
3 of the disease at the time of writing, and 
patient 2 was at the most severe stage 4. 
Patient 4 was commenced on isoprinosine 
after the product was imported from abroad 
with approval from the Medicines Control 
Council and the local pharmacy therapeutics 
committee. Motivations are in place for the 
remaining patients.
Discussion
In children aged <5 years, measles is the 
second most common cause of death due 
to a vaccine-preventable disease, and it 
is in the top ten causes of death due to 
infectious diseases.[6] The World Health 
Organization predicts an increase in the 
numbers of measles cases and deaths as a 
result of logistical and financial challenges 
affecting vaccination coverage.[7] In 2009, the 
US Centers for Disease Control published a 
report supporting this statement, and in the 
same year this is exactly what transpired in 
SA.[1,7] Between 2009 and 2010, 28 African 
countries reported measles outbreaks.[8] In 
Europe measles outbreaks were reported in 
36 of the 53 European member states between 
2009 and 2011, with the primary reason 
for the outbreaks reported to be failure to 
vaccinate susceptible popula tions. [9] Vaccine 
safety concerns and perceived fewer benefits 
from vaccinations were found to be leading 
reasons for parents delaying vaccination of 
their children or refusing to vaccinate.[10] 
The USA, which had declared itself ‘measles 
eliminated’ in 2000, issued a warning 
in 2014 of disease recrudescence due to 
im ported cases.[11] It can be concluded that 
this vaccine-preventable disease is far from 
contained.
There are three neurological compli-
cations following measles virus infection: 
acute disseminated encephalomyelitis, MIBE 
and SSPE.[6]
SSPE affects immune-competent and 
immune-compromised hosts. The virus 
is present in the brain, and the incidence 
is reported to be 1/10 000, increasing to 
1/2 500 in children who contracted measles 
under 5 years of age.[6] As in our patients, the 
condition occurs more commonly in boys 
than in girls.[6] The risk of central nervous 
system (CNS) infection is increased when 
infection with the measles virus occurs at 
a young age, especially <2 years, when the 
immune system is immature and residual 
maternal antibodies may still be present.[6] 
This was the case for the patients reported in 
this case series, all of whom were known or 
believed to have been infected with measles 
before 9 months of age. The pathogenesis of 
SSPE is poorly understood. Although viral 
antigen and RNA are abundant in the brain 
in both MIBE and SSPE, fever is unusual 
and the virus is difficult, if not impossible, 
to culture from CNS tissue. Resource-poor 
settings tend to have a higher incidence 
of measles infection than high-income 
countries and carry a higher burden of 
SSPE, although the condition may not be 
readily diagnosed.[6] It is not unusual for 
the diagnosis of SSPE to be challenging and 
delayed owing to preferential consideration 
of other diverse differential diagnoses. Over 
78% of patients were misdiagnosed in one 
large study of 307 patients, with the median 
time to diagnosis of SSPE being 6  months 
(range 0.2 - 96).[6] Similar challenges were 
evident with our patients. Even when the 
diagnosis was suspected, there were a 
number of barriers to diagnostic closure. 
Furthermore, in settings such as SA where 
there is a high burden of HIV infection, the 
Table 2. Clinical stages of progression of 
SSPE[6]
Stage Clinical features
1 Mental deterioration 
accompanied by alterations in 
personality
2 Myoclonus and often seizures
3 Progressive neurological 
deterioration marked by rigidity
4 Optic atrophy, akinetic mutism 
and coma
Fig. 3. EEG from patient 1 in sleep state 4 months after presentation, demonstrating profoundly 
attenuated background (b) with recurrent periodic generalised paroxysms (a) consistent with a burst 
suppression pattern. 
a a abb
Fig. 4. EEG from patient 2 in sleep state 4 months after presentation, demonstrating slow attenuated 
background and recurrent periodic generalised spike and wave (a) and polyspike discharges (b) with 
suppression in between discharges. 
b b bba
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incidence may be expected to be further 
increased. Children of HIV-infected mothers 
are at particular risk of acquiring measles 
early, even before 9 months of age, which 
is the recommended age for vaccination in 
resource-limited settings.[6]
The average time to onset of SSPE after 
measles is 6 - 10 years (range 1 - 24). [6] The 
onset is insidious and the diagnosis is often 
not suspected early in the disease. [6] All the 
children in our series presented before 6 years 
of age and the SSPE followed an aggressive 
course, rapidly reaching either stage 3 or 4 
disease. Patient 3 presented with swelling of 
the optic discs, which was identified during 
his acute management when he presented 
with seizures and regression. This finding, 
in combination with positive oligoclonal 
bands, led to extended screening for 
antibodies related to anti-NMDA (N-methyl 
D-aspartate) receptor antibody encephalitis, 
which was negative. The association of 
ocular and visual manifestations is reported 
in SSPE and was found in 42.5% of patients 
with SSPE in one study; the optic disc 
swelling in our patient 3 was in keeping 
with a diagnosis of SSPE.[12,13] There are four 
stages to the disease, which are summarised 
in Table 2. Death occurs within months to 
years after onset.[6]
The diagnosis of SSPE is usually con-
firmed by a combination of elevated levels 
of anti body to measles virus in the serum 
and CSF and detection of characteristic 
periodic slow-wave complexes on an EEG.[6] 
The EEGs (Figs 3 - 6) in our patients were 
helpful and supportive of the diagnosis of 
SSPE. Neuroimaging is generally unhelpful, 
findings often being normal in the early 
stages of the disease, and the focal or 
diffuse T2-weighted hyperintense lesions 
that appear later are not pathognomonic. [6] 
This was the case in our patients; even 
patient  3, who developed extensive white 
matter hyperintensities, would have had a 
wide range of differential diagnoses with-
out the finding of raised CSF measles anti-
bodies that supported a diagnosis of SSPE. 
While in our patients the seizure presen-
tation was a major indicator of a more 
complex condition, all had been well before 
their abrupt onset of cognitive dysfunction 
and seizures. Their seizures were very 
stereotyped, persistent and resistant to 
typical medical interventions. Despite 
relatively early suspicion of SSPE, the initial 
lack of history of infection and negative 
CSF PCR results were misleading. It was 
only with persistence (largely on the part of 
author AN) that the history of prior measles 
infection was confirmed in all, after which 
pursuit of the correct screening in the CSF, 
namely the measles antibody titres, enabled 
the diagnosis to be confirmed. Viral nucleic 
acid is rarely found in the CSF of patients 
with SSPE.[14]  This is due to absence of a 
typical productive infection of the brain 
with extracellular release of virus. In the 
case of patients with SSPE, only the genome 
and nucleocapsid replicates and these 
spread from cell to adjacent cell through 
membrane fusion across synapses. Viral 
nucleic acid will therefore only be present in 
infected cells.  Findings were similar in the 
patients reported with MIBE, of whom only 
two were PCR-positive in the CSF.[5]
Numerous therapeutic agents, including 
amantadine, interferon, isoprinosine and 
ribavirin, have been used for treatment of 
SSPE. Evaluation of efficacy is difficult, 
as most cases are isolated and occur in 
small clusters.[6] The most commonly used 
regimen is a combination of isoprinosine and 
interferon-alpha, with some suggestion that 
this combination slows disease progression.[6] 
The latter intervention is not available in SA.
Turkey is in the unfortunate position 
of having significant experience in the 
condition. Guler et al.[15] reported 64 patients 
with SSPE, diagnosed at an average age 
of 12.3 years (range 5 - 17). None of the 
interventions attempted, including iso-
prinosine and interferon, altered the long-
term outcome. Furthermore, there was 
no difference between those who received 
isoprinosine in isolation and those receiving 
isoprinosine and interferon in combination. 
Guler et al. commented on high levels of 
Fig. 5. EEG of patient 3 in sleep state 2 months after presentation, showing a markedly abnormal 
recording with persistent spike and wave discharges (a) associated with myoclonic jerks and suppression 
(b) and compatible with electrical status. 
ba
Fig. 6A. Patient 4. EEG at presentation in sleep state, demonstrating a slow attenuated background 
with a generalised high-amplitude slow wave (a) which occurred periodically throughout the recording.
a
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consanguinity, and questioned whether an 
additional genetic modifying factor in their 
patients made them more susceptible to 
developing SSPE. A study from Karachi in 
Pakistan reported on 43 patients with similar 
clinical findings and outcomes.[16]
There are several implications for 
management, which is significantly deter-
mined by confirmation of the diagnosis, 
beyond the importance to the family of 
having diagnostic closure. Presentation 
with myoclonic or atonic seizures would 
normally preclude the use of carbamazepine, 
but for patients with SSPE this agent has the 
best seizure efficacy.[17-20] For our patient 
with HIV this led to further complications 
relating to the need for more aggressive 
monitoring of his HIV viral titres and the 
carbamazepine levels, owing to the risk of 
cross-reactivity with ART. An alternative 
agent could have been levetiracetam, but in 
fact careful monitoring of drug levels enabled 
carbamazepine to be used successfully. 
There are no data in the literature to guide 
a treatment care plan in the setting of SSPE 
and the immunocompromised patient, and 
colleagues in Turkey had not managed such 
a case (personal communication, B Anlar). 
This scenario is likely to be a uniquely 
African challenge.
Routine measles vaccination is the best 
approach for preventing SSPE.[6] Measles 
vaccine is a live attenuated vaccine, and 
vaccine strains have not caused SSPE. 
Furthermore, it is widely accepted that 
SSPE cannot occur in the absence of direct 
infection with wild-type measles virus.[6] 
The incidence of SSPE is directly related to 
the incidence of measles in a population, 
and has decreased dramatically since the 
introduction of measles vaccination.[6]
The four cases described here may repre-
sent only a proportion of the cases across 
SA. In addition, it is likely that the reported 
numbers of children infected during the 
measles outbreak are an underestimation, 
and further patients are therefore likely to 
present with SSPE. Children presenting with 
acute-onset intractable seizures, especially 
myoclonus and atonic siezures, and showing 
neuroregression should have a careful 
history of prior measles infection in infancy 
documented, and there should be a low 
threshold for screening for measles CSF 
antibodies.
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Fig. 6B. Patient 4. Follow-up EEG at 1 month in awake state, demonstrating normal posterior alpha 
rhythms with overriding 2 Hz generalised slow waves and periodic spike and slow wave (a) followed 
by 2 seconds of attenuation (b). This discharge correlated with a myoclonic seizure and was recurrent 
throughout the recording. 
a b
